Yogyakarta, October 7th, 2022 - PT Kimia Farma Tbk together with the National Research and Innovation Agency (BRIN) in the Annual Scientific Week of the Indonesian Nuclear and Molecular Teranostic Medicine Association, officially launched the first medicine to detect tuberculosis (TB) in Indonesia. This medicine is an innovation by the children of the nation as well as a tribute to fellow doctors and medical workers that is useful to help detect lung as well as extrapulmonary tuberculosis.
The event was attended by PT Kimia Farma Tbk’s Director Of Marketing, Research And Development, Dr. Jasmine Karsono; BRIN’s Head of Research Center for Radioisotope, Radiopharmaceuticals and Biodosimetry Technology, Dr. Tita Puspitasari, M. Si. with a research team; Head and Management of Indonesian Nuclear Doctors Association; as well as Nuclear and Molecular Teranostic Medicine, and Radiopharmacist Specialists.
“We are very proud and appreciate the TB-scan kit created by the children of the nation. TB-scan is the first innovative radiopharmaceutical kit product in Indonesia to detect TB. The launch of this product is a form of Kimia Farma’s commitment to help make the research downstream a success in which the benefits can be felt,” said Dr. Jasmine Karsono, Kimia Farma’s Director of Marketing, Research and Development at Marriott Yogyakarta Hotel, Friday (7/10).
Currently the supply of radiopharmaceuticals in Indonesia is 80% dominated by imported products, while the domestic market is still large. “The national pharmaceutical industry based on radiopharmaceuticals must be strengthened and widened, and supported by all stakeholders from regulations, up to date research, and incentives from the government as a driver for radiopharmaceutical industry independence,” said Dr. Tita Puspitasari M.Si, Head of Research Center for Radioisotope, Radiopharmaceuticals and Biodosimetry Technology at the National Research and Innovation Agency (BRIN).
Furthermore, Dr. Jasmine Karsono said, Kimia Farma has downstreamed other radiopharmaceutical kit researched by Research Center for Radioisotope, Radiopharmaceuticals and Biodosimetry Technology at the National Research and Innovation Agency (BRIN), such as MDP Kit to detect bone imaging. DTPA Kit to detect kidney perfusion and MIBI Kit to detect heart perfusion.
The Tuberculosis diagnostic pharmaceutical kit named TB-Scan (Ethambutol Kit) is a diagnostic kit that works based on radioactive mechanism that is clinically able to help detect and localize Extrapulmonary TB and Pulmonary TB disease, hence this medicine will help medical workers in establishing the diagnose and spread of TB.
TB-Scan has an excellent level of accuracy, sensitivity, specificity, and positive as well as negative predictive value. It makes TB-Scan the number one choice for medical workers to help detect and locate Extrapulmonary TB and Pulmonary TB inside the human body. This kit can be used both by children and adults because it is a non-invasive diagnostic.